Sanofi India Share Price Today (SANOFI)
TODAY IN ONE LINE
SANOFI edged up 0.8% on light volume, outperforming Nifty's -0.8% move.
With a market cap of ₹7,841.58 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Sanofi India flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 49.2% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 47.1%
- ●Healthy Operating MarginsOPM is structurally strong at 24.4%
- ●High Promoter HoldingPromoters hold 60.4% skin-in-the-game
- ●Steady Dividend YieldReliable 7.15% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 14.1% YoY
- ●Rising Receivables vs SalesReceivables grew 88.3% outpacing sales growth of 0.9%
Latest Sanofi India News
What changed recently?
Recent events, corporate actions, and announcements.
Sanofi India Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Sanofi India Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Sanofi India Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Sanofi India Limited — derived from the live tape, not yesterday's close.
Sanofi India Limited last traded at ₹3,410 with an intraday range of ₹3,354.1–₹3,416.5 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹3410.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3557.77 | +147.77 | +4.33% |
| R3 | 3495.37 | +85.37 | +2.50% |
| R2 | 3455.93 | +45.93 | +1.35% |
| R1 | 3432.97 | +22.97 | +0.67% |
| PIVOT | 3393.53 | -16.47 | -0.48% |
| CURRENT | 3410.00 | — | — |
| S1 | 3370.57 | -39.43 | -1.16% |
| S2 | 3331.13 | -78.87 | -2.31% |
| S3 | 3308.17 | -101.83 | -2.99% |
| S4 | 3245.77 | -164.23 | -4.82% |
SANOFI is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹3367.4–₹3406.4
Trading Inside opening range
Sanofi India Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Sanofi India Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Sanofi India Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹7,841.58 Cr. and reported EPS of ₹134.59.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Revenue from Operations | 2,851 | 2,013 ▼ 29.4% |
| Sales Growth YoY %Derived | — | -29.39% |
| Other Income | 65 | 17 ▼ 74.7% |
| Total Income | 2,916 | 2,030 ▼ 30.4% |
| 1,201 | 979 ▼ 18.5% | |
| Gross ProfitDerived | 1,650 | 1,034 ▼ 37.3% |
| Gross Margin %Derived | 57.88% | 51.36% |
| 846 | 543 ▼ 35.8% | |
| EBITDA (Operating Profit)Derived | 804 | 491 ▼ 38.9% |
| OPM %Derived | 28.19% | 24.38% |
| 59 | 1 ▼ 99.2% | |
| Profit Before Tax (PBT) | 846 | 431 ▼ 49.0% |
| 243 | 118 ▼ 51.5% | |
| Effective Tax %Derived | 28.69% | 27.28% |
| Profit/Loss from Discontinued Ops | — | 100 |
| Total Profit for Period | 603 | 314 ▼ 48.0% |
| Net Profit (Owner's PAT)Derived | 603 | 314 ▼ 48.0% |
| Net Profit Margin %Derived | 21.15% | 15.58% |
| PAT Growth YoY %Derived | — | -47.97% |
| Earnings Per Share (EPS ₹) | 261.78 | 179.46 ▼ 31.4% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 7 ▲ 653.8% |
| Total Expenses (incl. D&A & Interest) | 2,071 | 1,598 ▼ 22.8% |
| Material Cost % of RevenueDerived | 19.80% | 17.62% |
| Employee Cost % of RevenueDerived | 13.00% | 11.93% |
| Other Cost % of RevenueDerived | 16.69% | 15.05% |
| Interest Coverage (x)Derived | 449.47x | 302.73x |
| Period | Dec 2023 | Dec 2024 | Trend |
|---|---|---|---|
| Revenue from Operations | 2,851 | 2,013 ▼ 29.4% | |
| Sales Growth YoY %Derived | — | -29.39% | |
| Other Income | 65 | 17 ▼ 74.7% | |
| Total Income | 2,916 | 2,030 ▼ 30.4% | |
1,201 | 979 ▼ 18.5% | ||
| Gross ProfitDerived | 1,650 | 1,034 ▼ 37.3% | |
| Gross Margin %Derived | 57.88% | 51.36% | |
846 | 543 ▼ 35.8% | ||
| EBITDA (Operating Profit)Derived | 804 | 491 ▼ 38.9% | |
| OPM %Derived | 28.19% | 24.38% | |
59 | 1 ▼ 99.2% | ||
| Profit Before Tax (PBT) | 846 | 431 ▼ 49.0% | |
243 | 118 ▼ 51.5% | ||
| Effective Tax %Derived | 28.69% | 27.28% | |
| Profit/Loss from Discontinued Ops | — | 100 | |
| Total Profit for Period | 603 | 314 ▼ 48.0% | |
| Net Profit (Owner's PAT)Derived | 603 | 314 ▼ 48.0% | |
| Net Profit Margin %Derived | 21.15% | 15.58% | |
| PAT Growth YoY %Derived | — | -47.97% | |
| Earnings Per Share (EPS ₹) | 261.78 | 179.46 ▼ 31.4% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | 7 ▲ 653.8% | |
| Total Expenses (incl. D&A & Interest) | 2,071 | 1,598 ▼ 22.8% | |
| Material Cost % of RevenueDerived | 19.80% | 17.62% | |
| Employee Cost % of RevenueDerived | 13.00% | 11.93% | |
| Other Cost % of RevenueDerived | 16.69% | 15.05% | |
| Interest Coverage (x)Derived | 449.47x | 302.73x |
Sanofi India segment analysis : revenue and profit mix.
Disclosed business segments at Sanofi India with their share of revenue and profit, switchable between consolidated and standalone reporting.
Sanofi India discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Sanofi India Limited.
Our AI distills the core fundamental drivers supporting Sanofi India Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Sanofi India Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Exceptional ROE 47.10% and ROCE 49.20% vastly exceed pharmaceutical sector peers.
Operating margin 24.90% outpaces peer median ~16.2%, demonstrating superior pricing power.
Minimal debt-to-equity ratio 0.0002 ensures substantial financial flexibility and stability.
Promoter holding 60.40% signals strong long-term commitment and governance alignment.
Net profit margin 19.26% TTM reflects robust profitability above sector averages.
Key Risks.
TTM revenue declined 11.90% YoY, indicating significant demand headwinds and market pressure.
Latest quarterly EPS declined 14.10% YoY despite quarterly sales growth of 9.74%.
Payout ratio 178.37% exceeds earnings, representing unsustainable dividend distribution level.
P/E ratio 24.88x appears elevated relative to forward P/E 18.67x valuation compression.
FII holdings eased from 8.71% to 5.58%, signaling foreign investor caution and conviction erosion.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 42% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 3.58%.
Sanofi India Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Sanofi India Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Sanofi India Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Sanofi India Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Sanofi India Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Sanofi India Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Sanofi India Limited stood at 56.3% of traded volume, against a 20-day average of 58.8%.
Sanofi India announcements: results, concalls, ratings, M&A.
Filings Sanofi India sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Sanofi India files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 133 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Please find enclosed certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June…
General Updates
Sanofi India Limited has informed the Exchange about disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)…
Trading Window
Sanofi India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
General Updates
Sanofi India Limited has informed the Exchange about disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)…
Disclosure under SEBI Takeover Regulations
Sanofi India Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Investor decks & rating reports.
Sanofi India dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Sanofi India has declared, sequenced by announce and record date.
Sanofi India corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Sanofi India Limited: business, sector, key facts.
What Sanofi India Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Sanofi India Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SANOFI, BSE: 500674.
Sanofi India Limited is a prominent pharmaceutical company with a significant global presence, operating in India, Singapore, and other international markets. Its core business revolves around the manufacturing, trade, and distribution of a diverse range of pharmaceutical products catering to various therapeutic areas.
The company's portfolio encompasses a wide spectrum of treatments, including medications for diabetes management (Lantus, Toujeo, Soliqua), cardiovascular health (Clexane, Cardace, Lasix), infectious diseases (Targocid), neurological conditions (Frisium), and other therapeutic areas such as allergy, pain management, digestive health, and nutritional support. These products are marketed under well-established brand names such as Amaryl, Lasilactone, Glimepiride, Cetapin, Combiflam, Allegra, Baralgan, and others.
Sanofi India's distribution network extends to numerous countries, with exports reaching approximately 24 different nations. This broad reach underscores the company's international standing and the demand for its products across diverse geographical regions. The company relies on a network of independent distributors to reach its target markets effectively.
With a history dating back to 1956, Sanofi India Limited has undergone name changes, previously operating as Aventis Pharma Limited before its current iteration. The company's headquarters are located in Mumbai, India, and it maintains its subsidiary status under Hoechst GmbH, highlighting its established position within the broader pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Sanofi India Limited (SANOFI).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Sanofi India Limited (SANOFI)?
The current share price of Sanofi India Limited (SANOFI) is ₹3,410. Today, the stock has gained by ₹26.70 (0.79%), trading in a range of ₹3,354.1 to ₹3,416.5. The stock opened at ₹3,406.4 with a trading volume of 7,915 shares.
02Is Sanofi India Limited stock a good investment for long-term?
Sanofi India Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹7,841.58 crores, P/E ratio of 0.00, ROE of 47.10%, and ROCE of 49.20%. The dividend yield stands at 7.15%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Sanofi India Limited stock?
The 52-week high price of Sanofi India Limited (SANOFI) is ₹5,955, while the 52-week low is ₹3,054. Currently trading at ₹3,410, the stock is 12.3% away from its 52-week low and 42.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Sanofi India Limited stock at the current price?
Whether to buy Sanofi India Limited stock at ₹3,410 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 0.00. Today's performance shows a gain of 0.79%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Sanofi India Limited and when is the next dividend?
Sanofi India Limited offers a dividend yield of 7.15%, which means for every ₹100 invested at the current price of ₹3,410, you can expect to receive approximately ₹7.15 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Sanofi India Limited?
Sanofi India Limited's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 0.00, ROE: 47.10%, ROCE: 49.20%, Dividend Yield: 7.15%, EPS: ₹134.59, Book Value: ₹325.31, and Debt-to-Equity: 0.02. The company's market cap stands at ₹7,841.58 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Sanofi India Limited stock performing today in the market?
Sanofi India Limited stock opened at ₹3,406.4 and is currently trading at ₹3,410, showing a gain of ₹26.70 (0.79%). The intraday high is ₹3,416.5 and low is ₹3,354.1. The trading volume stands at 7,915 shares, indicating moderate market participation today.
08What is the P/E ratio of Sanofi India Limited and what does it indicate?
Sanofi India Limited has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹134.59, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Sanofi India Limited (SANOFI) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.